Changes in quality of life and dyspnoea after hospitalization in COVID-19 patients discharged at home

  • Pierachille Santus | pierachille.santus@unimi.it Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan, Italy. https://orcid.org/0000-0003-3462-8253
  • Francesco Tursi Azienda Socio Sanitaria Territoriale di Lodi, Dipartimento Medico, USC Pneumologia, USS Servizio di Pneumologia, Ospedale di Codogno, Lodi, Italy., Italy.
  • Giuseppe Croce Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan, Italy. https://orcid.org/0000-0003-0992-881X
  • Chiara Di Simone Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan, Italy.
  • Francesca Frassanito Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan, Italy.
  • Paolo Gaboardi Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan, Italy. https://orcid.org/0000-0002-1974-0506
  • Andrea Airoldi Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan, Italy.
  • Marica Pecis Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan, Italy. https://orcid.org/0000-0001-8120-0730
  • Giangiuseppe Negretto Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan, Italy.
  • Dejan Radovanovic Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan, Italy. https://orcid.org/0000-0002-9013-3418

Abstract

Background: To date, the effects of COVID-19 pneumonia on health-related quality of life (HRQoL) and dyspnea are unknown.
Methods: In a real-life observational study, 20 patients with COVID-19-related pneumonia received usual care plus erdosteine (300 mg twice daily) for 15 days after hospital discharge following local standard operating procedures. At discharge (T0) and on Day 15 (T1), participants completed the St George’s Respiratory Questionnaire (SGRQ), the modified Medical Research Council (mMRC) scale of dyspnoea during daily activity, the BORG scale for dyspnoea during exertion, and Visual Analogue Scale (VAS) for dyspnoea at rest. Paired t-tests compared scores at T0 and T1.
Results: The mean (SD) SGRQ total score decreased from 25.5 (15.5) at T0 to 16.9 (13.2) at T1 (p<0.01); 65% of patients achieved a clinically important change of ≥4 points. SGRQ domain scores (symptoms, activity, and impact) were also significantly reduced (all p<0.01). The mean (SD) VAS score decreased from 1.6 (1.7) to 1.4 (2.5); p<0.01. The mean mMRC score decreased significantly (p=0.031) and 30% of patients achieved a clinically important change of ≥1 point. The mean (SD) Borg score increased from 12.8 (4.2) to 14.3 (2.4); p<0.01.
Conclusion: The present proof of concept study is the first to report HRQoL in patients with COVID-19. During 15 days after hospital discharge, patients reported significant improvements in HRQoL and dyspnoea at rest and during daily activities.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Author Biographies

Pierachille Santus, Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan

Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano

Giuseppe Croce, Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan

Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano

Chiara Di Simone, Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan

Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano

Francesca Frassanito, Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan

Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano

Paolo Gaboardi, Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan

Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano

Published
2020-10-13
Info
Issue
Section
Original Research Articles
Conflict of interest statement
Prof. Pierachille Santus reports research grants from Chiesi Farmaceutici, AirLiquide, Pfizer, Almirall, AstraZeneca, Edmond Pharma and Boehringer Ingelheim; personal fees from AstraZeneca, Boehringer Ingelheim, Edmond Pharma, Novartis, Menarini International, Guidotti, Mundipharma, Valeas, Berlin-Chemie and Zambon. Dr. Dejan Radovanovic reports personal fees from Astra Zeneca, Boehringer Ingelheim and Neopharmed Gentili. Drs. Francesco Tursi, Giuseppe Croce, Chiara Di Simone, Francesca Frassanito, Paolo Gaboardi, Andrea Airoldi, Marica Pecis and Giangiuseppe Negretto have no conflicts of interest to report.
Supporting Agencies
The study was part of the project on “Respiratory Diseases in patients with COVID-19 patients” funded by the Department of Biomedical and Clinical Sciences “L. Sacco” – DIBIC – of the University of Milan.
Keywords:
Antioxidant, coronavirus, COVID-19, dyspnoea, erdosteine, quality of life
Statistics
  • Abstract views: 672

  • PDF: 83
  • HTML: 0
How to Cite
Santus, P., Tursi, F., Croce, G., Di Simone, C., Frassanito, F., Gaboardi, P., Airoldi, A., Pecis, M., Negretto, G., & Radovanovic, D. (2020). Changes in quality of life and dyspnoea after hospitalization in COVID-19 patients discharged at home. Multidisciplinary Respiratory Medicine, 15. https://doi.org/10.4081/mrm.2020.713